Fig 1: Tau proteolysis map and in vitro fluorescence protease assays. a A peptide library tiling across tau was incubated with individual lysosomal proteases (left). At various times and pHs, the reaction was subjected to MSP-MS to detect proteolytic cleavage sites in tau. The amino acid sequence of tau is in black letters at the top. Cleavage sites are indicated with the enzyme letter (e.g., B for CTSB) positioned at the P1 position (e.g. the B for CTSB is at amino acid position 7, so the cleavage occurs between positions 7 and 8). A total of 285 cleavages were found. Autosomal-dominant coding mutations associated with frontotemporal dementia are noted in red above the tau sequence. Grey bars highlight amino acid mutations tested in in vitro fluorescent protease assays. b Pie chart demonstrating the number of cleavages sites within the tau sequence for each protease with the percentage of contributed cleavage sites in parentheses. c Table of maximal velocity (Vmax) ratios (mutant/WT), comparing protease cleavage of WT versus mutant tau peptides. A grey box denotes a mutation which was predicted to be "non-damaging." Mutations disrupting protease cleave by 0–25% (1 point), 25–75% (2 points), and > 75% (3 points) are highlighted in light pink, dark pink, and dark red, respectively. Mutations augmenting the rate cleavage (-1 point) are highlighted in light green. Mutations with similar rate of cleavage compared to WT (0 points) are highlighted in yellow. Grey boxes denote no observed cleavage for either the WT or mutant peptide. Points were summed to derive a total “damage score”. d-i Representative curves of fluorescence generated from tau peptide cleavage, comparing WT and mutant peptides as labeled (n = 3 for all protease-substrate pairs). N1 and N2, N-terminal repeats; P1 and P2, proline-rich regions, R1-4, microtubule binding repeats 1–4; Æ, asparagine endopeptidase (AEP)
Fig 2: Compound displaying dual inhibitory activity against AIMP2 and α-synuclein aggregation without estrogenic activity(A) Trypan blue exclusion cell viability assessment conducted in SH-SY5Y cells transfected with Myc-AIMP2 or β-gal control (72 h) and treated with indicated compounds for AIMP2 and/or α-synuclein inhibitory activity (10 μM, 48 h) (n = 6 per group).(B) Quantification of estrogen responsive gene, EBAG9 messenger RNA levels in the human breast tumor cell line, MCF7 treated with the indicated compounds (10 μM, 48 h) (n = 5 separate experiments per group). GAPDH served as internal loading control for normalization.(C) Dot blot assessment of biotin-conjugated SG13-136 (SG13-158: 0, 2, 4, 8, 16, and 32 nmol) binding to recombinant α-synuclein (αSyn) or/and AIMP2 (1 μg). SG13-136 binding to recombinant GST, Tau, and ZNF746 (1 μg) was also monitored to determine the specificity of SG13-136 binding to α-synuclein and AIMP2.(D) Binding curve depicting increasing doses of biotin-conjugated SG13-136 for each recombinant protein in the dot blot assay. Dissociation constant (Kd) values of biotin-conjugated SG13-136 binding to α-synuclein and AIMP2 are provided. Data in all panels represent mean ± standard error of the mean. ∗p < 0.05 and ∗∗∗p < 0.001, determined by one-way (B) or two-way (A) analysis of variance (ANOVA) followed by Tukey’s post hoc analysis. n.s., non-significant.
Supplier Page from Abcam for Recombinant Human Tau protein